Abstract: Provided are a niraparib sustained and controlled release pharmaceutical composition and use thereof. The sustained and controlled release pharmaceutical composition contains dissolution-improved niraparib and a matrix polymer used for regulating release rate; the steady-state plasma concentration trough value Cmin,ss of the pharmaceutical composition is 0.5-4 ?M; the steady-state plasma concentration peak value Cmax,ss is 0.8-6 ?M.